Rotavirus W179-9 vaccine - Merck & Co

Drug Profile

Rotavirus W179-9 vaccine - Merck & Co

Alternative Names: Pentavalent human-bovine reassortant rotavirus vaccine - Merck; RotaTeq; Rotavirus vaccine, live, oral, pentavalent; SUB 25745; V260; W179-9

Latest Information Update: 05 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Banyu; Chongqing Zhifei Biological Products; Merck & Co
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Rotavirus infections

Most Recent Events

  • 16 Apr 2018 Rotavirus vaccine licensed to Chongqing Zhifei Biological Products in China before April 2018
  • 16 Apr 2018 Launched for Rotavirus infections (In children, In infants, Prevention) in China (PO) after April 2018
  • 13 Apr 2018 Registered for Rotavirus infections (In infants, Prevention, In children) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top